Decitabine induces regulatory T cells, inhibits the production of IFN-gamma and IL-17 and exerts preventive and therapeutic efficacy in rodent experimental autoimmune neuritis.

Abstract

Guillain-Barré syndrome (GBS) is an immune-mediated acute disorder of the peripheral nervous system. Despite treatment, there is an associated mortality and severe disability in 9 to 17% of the cases. Decitabine (DAC) is a hypomethylating drug used in myelodisplastic syndrome, that has been shown to exert immunomodulatory effects. We have evaluated the effects of DAC in two rodent models of GBS, the Experimental Allergic Neuritis (EAN). Both prophylactic and therapeutic treatment with DAC ameliorated the clinical course of EAN, increasing the numbers of thymic regulatory T cells and reducing the production of proinflammmatory cytokines. Our data suggest the possible use of decitabine for the treatment of GBS.

• Authors: Paolo Fagone, Emanuela Mazzon, Tinatin Chikovani, Andrea Saraceno, Santa Mammana, Giuseppe Colletti, Katia Mangano, Placido Bramanti, Ferdinando Nicoletti
• Journal: Journal of neuroimmunology (J Neuroimmunol) Vol. 321 Pg. 41-48 (08 15 2018) ISSN: 1872-8421 [Electronic] Netherlands
• PMID: 29957387 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: Copyright © 2018 The Authors. Published by Elsevier B.V. All rights reserved.

Chemical References

• Enzyme Inhibitors
• Interleukin-17
• Decitabine
• Interferon-gamma

Topics

• Animals
• Decitabine (pharmacology)
• Enzyme Inhibitors (pharmacology)
• Interferon-gamma (biosynthesis, drug effects)
• Interleukin-17 (biosynthesis)
• Male
• Mice
• Mice, Inbred C57BL
• Neuritis, Autoimmune, Experimental (immunology, pathology)
• Rats
• Rats, Inbred Lew
• T-Lymphocytes, Regulatory (drug effects, immunology)